IRADIMED CORP (IRMD)
US46266A1097 - Common Stock
IRMD gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IRMD a very profitable company, without any liquidiy or solvency issues. IRMD is not overvalued while it is showing excellent growth. This is an interesting combination. With these ratings, IRMD could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
IRMD had positive earnings in the past year.
IRMD had a positive operating cash flow in the past year.
IRMD had positive earnings in each of the past 5 years.
In the past 5 years IRMD always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 19.76%, IRMD belongs to the top of the industry, outperforming 97.86% of the companies in the same industry.
With an excellent Return On Equity value of 22.33%, IRMD belongs to the best of the industry, outperforming 96.26% of the companies in the same industry.
The Return On Invested Capital of IRMD (19.59%) is better than 98.93% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IRMD is significantly above the industry average of 8.19%.
The last Return On Invested Capital (19.59%) for IRMD is above the 3 year average (15.74%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.76% | ||
| ROE | 22.33% | ||
| ROIC | 19.59% |
ROA(3y)14.97%
ROA(5y)12.26%
ROE(3y)18.14%
ROE(5y)14.8%
ROIC(3y)15.74%
ROIC(5y)N/A
1.3 Margins
IRMD has a Profit Margin of 26.12%. This is amongst the best in the industry. IRMD outperforms 95.72% of its industry peers.
In the last couple of years the Profit Margin of IRMD has grown nicely.
IRMD has a Operating Margin of 29.91%. This is amongst the best in the industry. IRMD outperforms 97.33% of its industry peers.
IRMD's Operating Margin has improved in the last couple of years.
IRMD's Gross Margin of 77.14% is amongst the best of the industry. IRMD outperforms 89.84% of its industry peers.
IRMD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.91% | ||
| PM (TTM) | 26.12% | ||
| GM | 77.14% |
OM growth 3YN/A
OM growth 5Y9.17%
PM growth 3Y82.43%
PM growth 5Y4.85%
GM growth 3Y0.98%
GM growth 5Y0.05%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IRMD is creating value.
The number of shares outstanding for IRMD has been increased compared to 1 year ago.
The number of shares outstanding for IRMD has been increased compared to 5 years ago.
IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
IRMD has an Altman-Z score of 41.82. This indicates that IRMD is financially healthy and has little risk of bankruptcy at the moment.
IRMD has a better Altman-Z score (41.82) than 97.86% of its industry peers.
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 41.82 |
ROIC/WACC2.12
WACC9.23%
2.3 Liquidity
IRMD has a Current Ratio of 9.21. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IRMD (9.21) is better than 91.44% of its industry peers.
A Quick Ratio of 7.82 indicates that IRMD has no problem at all paying its short term obligations.
IRMD has a better Quick ratio (7.82) than 91.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.21 | ||
| Quick Ratio | 7.82 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.48% over the past year.
Measured over the past years, IRMD shows a very strong growth in Earnings Per Share. The EPS has been growing by 22.34% on average per year.
IRMD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.24%.
IRMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.58% yearly.
EPS 1Y (TTM)13.48%
EPS 3Y53.4%
EPS 5Y22.34%
EPS Q2Q%0%
Revenue 1Y (TTM)13.24%
Revenue growth 3Y27.38%
Revenue growth 5Y16.58%
Sales Q2Q%11.03%
3.2 Future
The Earnings Per Share is expected to grow by 14.01% on average over the next years. This is quite good.
IRMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.79% yearly.
EPS Next Y14.06%
EPS Next 2Y9.82%
EPS Next 3Y14.01%
EPS Next 5YN/A
Revenue Next Year11.28%
Revenue Next 2Y11.02%
Revenue Next 3Y14.79%
Revenue Next 5YN/A
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 34.17 indicates a quite expensive valuation of IRMD.
Compared to the rest of the industry, the Price/Earnings ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 72.19% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of IRMD to the average of the S&P500 Index (27.55), we can say IRMD is valued slightly more expensively.
The Price/Forward Earnings ratio is 30.63, which means the current valuation is very expensive for IRMD.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 73.80% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.00. IRMD is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.17 | ||
| Fwd PE | 30.63 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IRMD is valued a bit cheaper than 71.66% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, IRMD is valued cheaper than 80.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 40.38 | ||
| EV/EBITDA | 29.13 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
IRMD has an outstanding profitability rating, which may justify a higher PE ratio.
IRMD's earnings are expected to grow with 14.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.43
PEG (5Y)1.53
EPS Next 2Y9.82%
EPS Next 3Y14.01%
5. Dividend
5.1 Amount
IRMD has a Yearly Dividend Yield of 1.12%. Purely for dividend investing, there may be better candidates out there.
IRMD's Dividend Yield is rather good when compared to the industry average which is at 1.68. IRMD pays more dividend than 94.65% of the companies in the same industry.
With a Dividend Yield of 1.12, IRMD pays less dividend than the S&P500 average, which is at 2.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.12% |
5.2 History
IRMD has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
63.24% of the earnings are spent on dividend by IRMD. This is not a sustainable payout ratio.
DP63.24%
EPS Next 2Y9.82%
EPS Next 3Y14.01%
IRADIMED CORP
NASDAQ:IRMD (12/27/2024, 4:19:38 PM)
After market: 54.67 0 (0%)54.67
-0.35 (-0.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners56.06%
Inst Owner Change-0.37%
Ins Owners37.01%
Ins Owner Change1.37%
Market Cap692.67M
Analysts82.5
Price Target61.2 (11.94%)
Short Float %1.08%
Short Ratio2.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.12% |
Dividend Growth(5Y)N/A
DP63.24%
Div Incr Years1
Div Non Decr Years1
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.16%
Min EPS beat(2)9.5%
Max EPS beat(2)12.81%
EPS beat(4)3
Avg EPS beat(4)6.01%
Min EPS beat(4)-3.61%
Max EPS beat(4)12.81%
EPS beat(8)7
Avg EPS beat(8)7.79%
EPS beat(12)11
Avg EPS beat(12)12.18%
EPS beat(16)14
Avg EPS beat(16)13.5%
Revenue beat(2)0
Avg Revenue beat(2)-0.57%
Min Revenue beat(2)-0.72%
Max Revenue beat(2)-0.41%
Revenue beat(4)1
Avg Revenue beat(4)-0.42%
Min Revenue beat(4)-1.28%
Max Revenue beat(4)0.72%
Revenue beat(8)4
Avg Revenue beat(8)0.01%
Revenue beat(12)5
Avg Revenue beat(12)-0.19%
Revenue beat(16)8
Avg Revenue beat(16)1.2%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.35%
EPS NY rev (1m)0%
EPS NY rev (3m)5.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.17 | ||
| Fwd PE | 30.63 | ||
| P/S | 9.71 | ||
| P/FCF | 40.38 | ||
| P/OCF | 29.41 | ||
| P/B | 8.3 | ||
| P/tB | 8.6 | ||
| EV/EBITDA | 29.13 |
EPS(TTM)1.6
EY2.93%
EPS(NY)1.79
Fwd EY3.27%
FCF(TTM)1.35
FCFY2.48%
OCF(TTM)1.86
OCFY3.4%
SpS5.63
BVpS6.59
TBVpS6.36
PEG (NY)2.43
PEG (5Y)1.53
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.76% | ||
| ROE | 22.33% | ||
| ROCE | 24.74% | ||
| ROIC | 19.59% | ||
| ROICexc | 49% | ||
| ROICexgc | 53.49% | ||
| OM | 29.91% | ||
| PM (TTM) | 26.12% | ||
| GM | 77.14% | ||
| FCFM | 24.06% |
ROA(3y)14.97%
ROA(5y)12.26%
ROE(3y)18.14%
ROE(5y)14.8%
ROIC(3y)15.74%
ROIC(5y)N/A
ROICexc(3y)61.12%
ROICexc(5y)N/A
ROICexgc(3y)67.67%
ROICexgc(5y)N/A
ROCE(3y)19.88%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y3.9%
ROICexc growth 3YN/A
ROICexc growth 5Y3.72%
OM growth 3YN/A
OM growth 5Y9.17%
PM growth 3Y82.43%
PM growth 5Y4.85%
GM growth 3Y0.98%
GM growth 5Y0.05%
F-Score8
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 772.64% | ||
| Cap/Sales | 8.97% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 106.32% | ||
| Profit Quality | 92.1% | ||
| Current Ratio | 9.21 | ||
| Quick Ratio | 7.82 | ||
| Altman-Z | 41.82 |
F-Score8
WACC9.23%
ROIC/WACC2.12
Cap/Depr(3y)459.84%
Cap/Depr(5y)293.36%
Cap/Sales(3y)5.84%
Cap/Sales(5y)4.16%
Profit Quality(3y)69.37%
Profit Quality(5y)137.47%
High Growth Momentum
Growth
EPS 1Y (TTM)13.48%
EPS 3Y53.4%
EPS 5Y22.34%
EPS Q2Q%0%
EPS Next Y14.06%
EPS Next 2Y9.82%
EPS Next 3Y14.01%
EPS Next 5YN/A
Revenue 1Y (TTM)13.24%
Revenue growth 3Y27.38%
Revenue growth 5Y16.58%
Sales Q2Q%11.03%
Revenue Next Year11.28%
Revenue Next 2Y11.02%
Revenue Next 3Y14.79%
Revenue Next 5YN/A
EBIT growth 1Y11.47%
EBIT growth 3YN/A
EBIT growth 5Y27.27%
EBIT Next Year6.28%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y95.17%
FCF growth 3Y1.76%
FCF growth 5Y-5.18%
OCF growth 1Y127.12%
OCF growth 3Y32.26%
OCF growth 5Y12.78%